Aster Investment Management’s Haemonetics HAE Stock Holding History

Aster Investment Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$18.2M	Buy	+439,500	New	+$17.8M	0.68%	54

Other funds holding HAE

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Aster Investment Management's HAE Position: Q2 2013 in Review

Aster Investment Management opened a new position in Haemonetics (HAE) in Q2 2013: 439,500 shares worth $18.2M. The stake represents 0.68% of the portfolio and ranks #54 among its holdings.

195 funds tracked by Wall St. Rank hold HAE as of Q2 2013.

Aster Investment Management held 439,500 shares of Haemonetics worth $18.2M as of Q2 2013.
Haemonetics was a new Aster Investment Management position in Q2 2013.
Haemonetics made up 0.68% of Aster Investment Management's portfolio in Q2 2013, its #54 holding.
195 funds tracked by Wall St. Rank held Haemonetics as of Q2 2013.

Based on Aster Investment Management's 13F filing for Q2 2013, filed 29 Jul 2013.